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Abstract
Background
Opportunistic chlamydia screening of <25 year-olds was nationally-implemented in England
in 2008 but its impact on chlamydia transmission is poorly understood. We undertook a pop-
ulation-based seroprevalence study to explore the impact of screening on cumulative inci-
dence of chlamydia, as measured by C.trachomatis-specific antibody.
Methods
Anonymised sera from participants in the nationally-representative Health Surveys for
England (HSE) were tested for C.trachomatis antibodies using two novel Pgp3 enzyme-
linked immunosorbent assays (ELISAs) as a marker of past infection. Determinants of being
seropositive were explored using logistic regression among 16–44 year-old women and
men in 2010 and 2012 (years when sexual behaviour questions were included in the survey)
(n = 1,402 women; 1,119 men). Seroprevalence trends among 16–24 year-old women
(n = 3,361) were investigated over ten time points from 1994–2012.
Results
In HSE2010/2012, Pgp3 seroprevalence among 16–44 year-olds was 24.4% (95%CI 22.0–
27.1) in women and 13.9% (11.8–16.2) in men. Seroprevalence increased with age (up to
33.5% [27.5–40.2] in 30–34 year-old women, 18.7% [13.4–25.6] in 35–39 year-old men);
years since first sex; number of lifetime sexual partners; and younger age at first sex. 76.7%
of seropositive 16–24 year-olds had never been diagnosed with chlamydia. Among 16–24
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year-old women, a non-significant decline in seroprevalence was observed from 2008–2012
(prevalence ratio per year: 0.94 [0.84–1.05]).
Conclusion
Our application of Pgp3 ELISAs demonstrates a high lifetime risk of chlamydia infection
among women and a large proportion of undiagnosed infections. A decrease in age-specific
cumulative incidence following national implementation of opportunistic chlamydia screen-
ing has not yet been demonstrated. We propose these assays be used to assess impact of
chlamydia control programmes.
Background
Genital infection with Chlamydia trachomatis (‘chlamydia’) is the most commonly-diagnosed
sexually transmitted infection (STI) in the UK,[1] and an important cause of pelvic inflamma-
tory disease, ectopic pregnancy and tubal factor infertility in women[2–5]. Many chlamydia
infections are asymptomatic[6;7] so can go undiagnosed. In England, the National Chlamydia
Screening Programme (NCSP) recommends opportunistic screening for chlamydia annually
and on change of sexual partner for sexually-active under-25 year-olds with the aim of detect-
ing and treating asymptomatic infections to reduce transmission and complications[8]. The
national implementation and scale-up of the NCSP in 2008 drove a large increase in chlamydia
screening, such that 2.3 million tests were reported in 2010 among 15- to 24-year-olds, equiva-
lent to 44% of women and 24% of men in this age group[9].
Chlamydia screening at the levels now seen in England is expected to reduce the incidence
and prevalence of chlamydia infection among the general population[10]. However, evaluating
the real-world impact of chlamydia screening presents a considerable challenge, in part due to
the absence of a robust outcome measure. Routine data on chlamydia diagnoses do not pro-
vide good evidence of chlamydia incidence or prevalence in the general population as infec-
tions are often asymptomatic and numbers of diagnoses depend on the proportion and risk
characteristics of the population tested[2;11]. Population-based estimates of the prevalence of
current chlamydia infections (i.e. using nucleic acid amplification tests, NAATs) are resource-
intensive and hard to achieve[12].
Given these challenges, studies that measure the prevalence of antibodies in serum have
been proposed as a means of evaluating the impact of chlamydia control programmes[13].
Serological testing for C.trachomatis-specific antibodies has previously been problematic as
available assays had poor sensitivity and specificity and were often cross-reactive with other
chlamydiae species[14;15]. In recent years, tests with better sensitivity and specificity have
become available and offer new potential for the evaluation of chlamydia control programmes
[16;17]Antibodies to the highly immunogenic and specific C.trachomatis Pgp3 protein[18;19]
persist following infection, thus providing a marker of past infection. This in turn allows esti-
mation of age-specific cumulative incidence, which should be informative for evaluating the
impact of chlamydia screening against its aims of reducing transmission[17;20].
We used data and stored sera from nationally-representative household surveys from 1994
to 2012 to explore sociodemographic and behavioural factors associated with serological evi-
dence of a previous infection and to evaluate the impact of widespread opportunistic chla-
mydia screening on age-specific cumulative incidence of chlamydia in England up to 2012.
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Methods
Participants
The Health Survey for England (HSE) is a nationally-representative survey carried out annu-
ally since 1991. Participants are invited to provide a blood sample for laboratory analyses and
storage for future research. Details of HSE methodology are reported elsewhere[21;22]. In
summary, each year’s survey used a stratified probability sampling design. Households were
selected annually from a national postcode list. Residents aged16 years (up to 10 per house-
hold) were eligible for interview (children were eligible but are not part of this study). Health
and sociodemographic information was collected using face-to-face interviews, self-completed
questionnaire booklets and a nurse visit. In 2010, HSE for the first time included questions on
sexual behaviours and chlamydia diagnosis history, collected using the self-completed booklet.
These were repeated in 2012.
Stored sera from HSE participants who had provided a specimen with informed consent
for future use were obtained from a) 16- to 44-year-old male and female HSE 2010 and HSE
2012 participants (hereafter HSE2010/2012) to explore factors associated with being Pgp3
seropositive and b) female participants aged 16 to 24 who took part in HSE years when stored
sera were available (1994–1996, 2001–02, and each year 2008–2012), to examine seropreva-
lence trends in the NCSP target age group. Time trends in men were not investigated due to
lower assay sensitivity[16;17].
Laboratory testing
Our testing strategy used two ‘in-house’ enzyme-linked immunosorbent assays (ELISAs)
based on the C.trachomatis-specific antigen Pgp3. Pgp3 is transcribed from the highly con-
served C.trachomatis cryptic plasmid, which has not been found in human C. pneumoniae iso-
lates[23] and has been found to be highly immunogenic in its native, trimeric form[18;19].
Pgp3 is thus a specific (i.e. not subject to cross-reaction) and potentially highly sensitive
marker of previous infection. Pgp3 is associated with the bacterial outer membrane and
secreted into the cell cytosol[24] and is a virulence factor supporting C.trachomatis infection
[25].
All specimens were first tested using an indirect Pgp3 ELISA, the performance characteris-
tics of which have been previously described.[16] Briefly, sensitivity to detect a previous
known infection was assessed among women and men with a clinical diagnosis of chlamydia
(range 0 to>1500 days between diagnosis and blood sample) and was found to be 73.8%
(66.5–79.9) in women and 44.2% (37.3–51.3) in men[16;20]. Specificity was estimated using
microimmunofluorescence (MIF)-negative paediatric sera to reduce likelihood of a previous
sexually-acquired C. trachomatis infection, and was found to be 97.6% (95%CI 96.2%-98.6%)
[16]. The second assay used in our testing strategy was a double-antigen sandwich ELISA
(hereafter ‘double-antigen ELISA’). As reported by Horner et al, the double-antigen ELISA has
demonstrated equivalent specificity (97.8%, 95% CI 96.5–99.1), but higher sensitivity (82.9%,
77.0–88.8 in women; 54.4%, 47.2–61.6 in men) than the Pgp3 indirect ELISA when evaluated
against the same clinical samples[17]. As also reported by Horner et al the two assays used in
our detection strategy have been found to be more sensitive to detect a previous known infec-
tion than both the MIF, which detects C.trachomatis antibodies to the elementary body form
of the bacteria[26], and commercial assays that target the Major Outer Membrane Protein
(MOMP; Anilabsystems, SeroCT, Medac) [17]. In women, sensitivities of the Pgp3 double-
antigen and indirect ELISAs were found to be 23% and 12% higher respectively than the
best-performing commercial assay (Anilabsystems, sensitivity 59.5%)[17]. Among men, the
C. trachomatis Seroprevalence in England
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sensitivity was 14% and 7% greater than for the Anilabsystems assay (sensitivity 40.2%). Sensi-
tivity among men was lower than that seen in women for both Pgp3 ELISAs and the MOMP
and MIF assays[17].
Although the double-antigen ELISA has demonstrated higher sensitivity than the indirect
ELISA, the double-antigen ELISA requires around a 25-fold higher volume of sera. A separate
comparison of results from sera tested on both assays showed that the indirect ELISA has good
agreement with the double-antigen ELISA at low (<0.1) and high (>1.0) absorbance values.
[17] We therefore used the indirect ELISA for initial screening, with subsequent testing of sera
with absorbance values between 0.1 and 1.0 using the double-antigen ELISA to resolve ‘equivo-
cal’ specimens (Table 1).
Statistical analyses
Data were analysed in Stata 12.1 accounting for weighting, clustering and stratification.
Weights were applied in line with HSE analysis guidelines and included weights to correct for
uneven probability of selection and, from HSE2003 onwards, non-response weights to ensure
the sample is representative with regard to age, sex and region and to adjust for differential
participation in blood specimen collection by sociodemographic and general health variables
[27]. The sample size was determined by the number of residual sera available from the surveys
with consent for future testing.
The seroprevalence of Pgp3 antibodies (hereafter termed ‘Pgp3 seroprevalence’) among
HSE2010/2012 participants was estimated by sex, number of lifetime sexual partners and pre-
vious chlamydia diagnosis, regardless of reported sexual activity. Associations between having
Pgp3 antibodies detected in serum (‘Pgp3 seropositive’) and sociodemographic and beha-
vioural factors were then examined among participants reporting at least one sexual partner
by the time of the interview (hereafter termed ‘sexually-experienced’) using univariable and
multivariable logistic regression. Associations with deprivation were explored using a resi-
dence-based measure, the quintile of Index of Multiple Deprivation (IMD) for the lower-layer
super output area (LSOA) of residence (a geographical area of around 1,500 people[28]). Sex-
ual behaviour variables reflecting lifetime (years since first heterosexual sex, number of lifetime
sexual partners) and more recent exposures (number of sexual partners in the last year, con-
dom used at last sex) were included. Number of lifetime sexual partners was a priori consid-
ered the main mechanism of exposure to infection. Odds ratios (ORs) adjusted for number of
lifetime sexual partners were therefore calculated to reduce confounding of the association
between other predictor variables and being Pgp3 seropositive.
Pgp3 seroprevalence was estimated among 16- to 24-year-old women for years with avail-
able sera from 1994 to 2012. The trend in Pgp3 seroprevalence was estimated from 2008 (the
first year when the NCSP was nationally-available) to 2012 using a generalised linear model
with year entered as a continuous variable. Seroprevalence was explored by birth cohort
Table 1. Pgp3 antibody test result according to testing strategy.
Double-antigen sandwich ELISA result
Negative Positive
Indirect ELISA result (Absorbance range) Negative (<0.1) Pgp3 negative N/A: Not re-tested
Negative (0.1–0.4730)* Pgp3 negative Pgp3 positive
Positive (0.4731–1.0) Pgp3 positive Pgp3 positive
Positive (>1.0) Pgp3 positive N/A: Not re-tested
*An absorbance (450-620nm) value of 0.473 is the cutoff for the indirect assay.
doi:10.1371/journal.pone.0152810.t001
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among women aged 16 to 24, with cohorts grouped to reflect their relative exposure to wide-
spread chlamydia screening. Women who were16 years in 2008 (the first year of national
implementation of the NCSP) were defined as having high screening exposure; those aged 17
to 24 in 2008 were defined as having partial screening exposure and those aged>24 years in
2008 were defined as having ‘limited’ screening exposure (see S1 File).
Ethical approval
The Health Survey for England is approved by an NHS research ethics committee each year.
This use of stored sera was approved by Yorkshire and Humber-South Yorkshire Research
Ethics Committee (ref:13/YH/0304). Participants included in this study all provided written
informed consent to participate in the survey, to provide blood samples, and to have these
stored for future anonymous testing as part of ethically approved research. Minors (those aged
16–17 years) provided their own informed consent; consent was not sought from parents or
guardians.
Results
Of 6,882 eligible participants, samples for 1,264 were unavailable due to a missing sample or
insufficient residual volume. Overall, 1,111/5,618 eligible participants with a valid antibody
test result were Pgp3 seropositive (see flow chart, S1 Fig).
Pgp3 seroprevalence in HSE2010/12
Overall Pgp3 seroprevalence among 16- to 44-year-olds in HSE2010/12 was 24.4% (95% CI
22.0–27.1) in women and 13.9% (11.8–16.2) in men, thus indicating the proportion of the pop-
ulation who had at least one antibody-inducing infection by the time of participating in the
survey. The lower seroprevalence in men may reflect the low sensitivity of the assays to detect
a previous known infection[16;17]. Among individuals who reported a previous chlamydia
diagnosis, 64.7% (51.9–75.6) of women and 43.9% (26.5–63.0) of men were Pgp3 seropositive.
Among sexually-experienced participants, Pgp3 seroprevalence increased with age and
years since first sex (Fig 1; Tables 2 and 3), with peak seroprevalence in women aged 30 to 34
(33.5%) and men aged 35 to 39 (18.7%). In women, those reporting10 lifetime sexual part-
ners had almost four-fold higher odds of being Pgp3 seropositive than those with 1–4 partners
(OR 3.84, 2.68–5.51). Being Pgp3 seropositive was also significantly associated with living in
more deprived areas, younger age at first sex, non-condom use in the last year, and reporting a
previous chlamydia diagnosis (Table 2, Fig 2). All variables associated with being Pgp3 sero-
positive in univariable analyses remained statistically significant after adjusting for number of
lifetime sexual partners.
In sexually-experienced men, similar factors were associated with being seropositive as seen
in women in univariable analyses although age group and deprivation of residence were not
statistically significant (Table 3, Fig 2). Men reporting10 lifetime sexual partners had almost
six-fold higher odds of being Pgp3 seropositive than those with 1–4 partners (OR 5.95, 3.41–
10.35). After adjusting for number of lifetime sexual partners, only reporting a previous diag-
nosis of chlamydia remained a significant predictor of being seropositive in men (AOR 3.55,
1.53–8.25).
Among Pgp3 seropositive individuals, 84.7% (80.3–88.3) of 16- to 44-year-olds did not
report a previous chlamydia diagnosis. This proportion varied by age group, whereby 76.7% of
16- to 24-year-olds, 79.0% of 25- to 34-year-olds and 92.9% of 35- to 44-year-olds did not
report a previous diagnosis. Among Pgp3 seropositive 16- to 24-year-olds, 36.1% (23.1–51.5)
had never been tested for chlamydia.
C. trachomatis Seroprevalence in England
PLOS ONE | DOI:10.1371/journal.pone.0152810 January 27, 2017 5 / 16
Pgp3 seroprevalence over time among 16- to 24-year-old women
Fig 3 shows Pgp3 seroprevalence among 16- to 24-year-old women across the time points
included between 1994 and 2012. There was no significant difference in Pgp3 seroprevalence
among these women between the first (1994–1996) and second (2001–2002) time-periods
sampled. Between 2008 and 2012, a non-significant decline was observed (prevalence ratio per
year: 0.94, 95%CI 0.84–1.05; p = 0.26). After stratifying by age group, there was no notable
trend among 16- to 19-year-olds (prevalence ratio: 0.96, 0.74–1.24; p = 0.76) and a non-signifi-
cant decline in Pgp3 seroprevalence among 20- to 24-year-olds (prevalence ratio: 0.92, 0.83–
1.04; p = 0.18).
Fig 4 shows Pgp3 seroprevalence by year of age and birth cohort defined by exposure to
chlamydia screening. Although only partial data were available on those with high exposure to
screening, there was no indication of a difference in the age-specific seroprevalence by birth
cohort, with similar age curves seen in each group.
Fig 1. Pgp3 seroprevalence by age group (1a & 1b) and by years since first heterosexual sex (1c & 1d)
(sexually-experienced 16- to 44-year-olds, HSE2010 & HSE2012). Solid lines show point estimates; dashed
lines show 95% confidence intervals. N shows unweighted denominators. 95% confidence intervals are not
shown in Fig 1a for 16–17 year-olds or in Fig 1b for those within 0–1 years of first heterosexual sex as no
individuals in this group were Pgp3 seropositive.
doi:10.1371/journal.pone.0152810.g001
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Table 2. Percentage Pgp3 seropositive by sociodemographic and sexual behavioural variables among sexually-experienced 16 to 44 year old
women (HSE2010 & HSE2012).
Pgp3 positive Unadjusted OR p Adjusted ORa
(95%CI)
p Denominator (W,
UW)b
% 95% CI OR 95% CI AOR 95%CI
Overall 25.8 (23.1–
28.6)
1423, 1194
Age group
16–19 6.3 (2.3–16.4) 1.00 Ref 0.002 1.00 Ref 0.009 114, 55
20–24 21.4 (15.3–
29.2)
4.05 (1.29–
12.78)
3.70 (1.17–
11.71)
255, 139
25–29 23.3 (17.1–
30.8)
4.50 (1.44–
14.07)
3.92 (1.26–
12.16)
229, 166
30–34 33.5 (27.5–
40.2)
7.50 (2.50–
22.54)
6.34 (2.11–
19.04)
284, 224
35–39 29.5 (24.2–
35.6)
6.23 (2.08–
18.65)
5.07 (1.71–
15.06)
240, 278
40–44 28.5 (23.2–
34.3)
5.91 (1.99–
17.60)
5.47 (1.84–
16.26)
302, 332
IMD quintile of LSOA of residencec
Least deprived 22.7 (17.1–
29.5)
1.00 Ref 0.033 1.00 Ref 0.037 256, 238
2 25.8 (20.3–
32.2)
1.18 (0.74–1.89) 1.08 (0.67–1.73) 292, 248
3 19.6 (15.1–
25.2)
0.83 (0.51–1.35) 0.83 (0.50–1.38) 309, 256
4 32.1 (26.1–
38.8)
1.61 (1.02–2.53) 1.61 (1.00–2.61) 290, 230
Most deprived 28.9 (22.7–
36.0)
1.38 (0.86–2.24) 1.46 (0.87–2.43) 276, 222
Age at first heterosexual sex
16+ at first intercourse 22.5 (19.6–
25.7)
1.00 Ref 0.000 1.00 Ref 0.004 1080, 911
<16 at first intercourse 39.6 (33.0–
46.6)
2.26 (1.61–3.16) 1.68 (1.18–2.39) 304, 246
Years since first heterosexual sex
0 to 4 8.1 (3.8–16.7) 1.00 Ref <0.001 1.00 Ref <0.001 184, 90
5 to 9 18.5 (13.1–
25.4)
2.56 (1.01–6.49) 2.05 (0.80–5.20) 289, 174
10 to 14 25.9 (20.1–
32.8)
3.95 (1.61–9.69) 2.79 (1.14–6.79) 256, 199
15 to 19 38.2 (32.0–
44.7)
6.96 (2.98–
16.26)
5.40 (2.31–
12.62)
271, 264
20+ 31.1 (26.5–
36.0)
5.08 (2.19–
11.77)
3.61 (1.55–8.37) 415, 461
Number of partners of the opposite sex in last
year
0 19.2 (11.7–
30.0)
1.00 Ref 0.370 1.00 Ref 0.028 91, 81
1 26.8 (23.8–
30.0)
1.53 (0.84–2.79) 1.58 (0.80–3.12) 1159, 993
2+ 25.7 (17.9–
35.4)
1.45 (0.69–3.06) 0.89 (0.41–1.94) 149, 103
Number of lifetime sexual partnersd
(Continued)
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Discussion
In 2010/2012, one quarter of women aged 16 to 44 and one in three of those aged 30 to 34 had
evidence of a previous antibody-inducing chlamydia infection. Being Pgp3 seropositive was
strongly associated with increasing age and numbers of lifetime sexual partners. Three quarters
of those under-25 with evidence of previous infection did not report a previous chlamydia
diagnosis, suggesting a high level of undiagnosed infections. There was no significant trend in
age-specific Pgp3 seroprevalence over time or between birth cohorts exposed to different levels
of opportunistic chlamydia screening.
A major strength of our study is our use of sera from a series of nationally-representative
samples, which incorporated sociodemographic and (in HSE2010/2012) sexual behavioural
data. We used assays that have demonstrated higher sensitivity and specificity than commer-
cially-available tests[16;17]. There were some limitations. Our findings may be affected by who
agreed to participate in the survey or provide a blood sample, although non-response weights
were applied to account for non-participation and HSE2010/2012 participants who contrib-
uted to this study were comparable to the overall HSE population on a range of sociodemo-
graphic and behavioural variables (S1 Table). Another limitation is that behavioural data were
self-reported. Sensitive items were collected using the self-completion booklet to minimise
Table 2. (Continued)
Pgp3 positive Unadjusted OR p Adjusted ORa
(95%CI)
p Denominator (W,
UW)b
% 95% CI OR 95% CI AOR 95%CI
1 to 4 16.5 (13.2–
20.3)
1.00 Ref <0.001
5 to 9 30.0 (25.0–
35.6)
2.18 (1.51–3.14)
10+ 43.1 (36.6–
49.8)
3.84 (2.68–5.51)
Was a condom used on any occasions in last 4
weeks?
Yes, used on every occasion 15.8 (11.4–
21.6)
1.00 Ref 0.001 1.00 Ref 0.001 262, 207
Yes, used on some occasions 19.4 (12.7–
28.5)
1.28 (0.68–2.41) 1.09 (0.57–2.09) 133, 95
No, not used in last 4 weeks 30.1 (26.4–
34.1)
2.30 (1.49–3.53) 2.17 (1.41–3.35) 735, 630
Not had vaginal or anal sex in last 4 weeks 26.8 (20.5–
34.3)
1.95 (1.15–3.31) 1.79 (1.03–3.11) 239, 209
Ever been told by a doctor that you have
chlamydia
No 23.6 (20.9–
26.7)
1.00 Ref <0.001 1.00 Ref <0.001 1145, 960
Yes 65.5 (52.7–
76.3)
6.12 (3.57–
10.51)
5.08 (2.79–9.23) 76, 68
aAdjusted for lifetime sexual partners only.
bAnalyses were conducted on those with non-missing data on the variable(s) of interest. Denominator totals vary due to item-missingness. W: Weighted;
UW: Unweighted.
cIMD: index of multiple deprivation; LSOA: Lower super output area
dIncludes partners of both the opposite and of the same sex.
doi:10.1371/journal.pone.0152810.t002
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Table 3. Percentage Pgp3 seropositive by sociodemographic and sexual behavioural variables among sexually-experienced 16 to 44 year old
men (HSE2010 & HSE2012).
Pgp3 positive Unadjusted OR p Adjusted ORa
(95%CI)
p Denominator (W,
UW)b
% 95% CI OR 95% CI AOR 95% CI
Overall 14.6 (12.3–
17.1)
1424, 948
Age group
16–19 4.1 (1.0–15.0) 1.00 - 0.113 1.00 - 0.385 142, 66
20–24 10.1 (5.8–17.0) 2.66 (0.57–
12.40)
1.74 (0.35–8.61) 220, 114
25–29 14.3 (9.2–21.5) 3.94 (0.88–
17.68)
2.32 (0.48–
11.20)
255, 139
30–34 18.1 (12.6–
25.3)
5.22 (1.19–
23.00)
3.21 (0.70–
14.76)
251, 165
35–39 18.7 (13.4–
25.6)
5.45 (1.24–
23.96)
3.22 (0.70–
14.76)
242, 214
40–44 16.7 (12.4–
22.1)
4.74 (1.09–
20.65)
2.74 (0.60–
12.62)
314, 250
IMD quintile of LSOA of residencec
Least deprived 13.7 (8.9–20.5) 1.00 Ref 0.680 1.00 Ref 0.795 241, 184
2 12.4 (8.5–17.8) 0.90 (0.47–1.72) 0.98 (0.50–1.92) 283, 195
3 14.8 (10.0–
21.3)
1.10 (0.56–2.14) 1.31 (0.65–2.61) 304, 199
4 13.8 (9.5–19.6) 1.01 (0.54–1.88) 0.90 (0.44–1.82) 285, 179
Most deprived 17.7 (12.7–
24.0)
1.36 (0.73–2.52) 1.22 (0.61–2.45) 310, 191
Age at first heterosexual sex
16+ at first intercourse 12.0 (9.6–15.0) 1.00 Ref 0.002 1.00 Ref 0.233 980, 658
<16 at first intercourse 22.6 (17.5–
28.8)
2.14 (1.41–3.24) 1.50 (0.94–
02.38)
357, 231
Years since first heterosexual sex
0 to 4 3.5 (1.1–10.5) 1.00 Ref 0.003 1.00 - 0.077 230, 109
5 to 9 10.1 (6.2–16.2) 3.11 (0.86–
11.18)
1.78 (0.47–6.82) 283, 154
10 to 14 16.3 (10.7–
24.0)
5.36 (1.51–
19.03)
3.12 (0.85–
11.42)
236, 148
15 to 19 22.3 (16.2–
29.8)
7.91 (2.31–
27.02)
4.10 (1.15–
14.66)
249, 186
20+ 18.0 (14.1–
22.6)
6.03 (1.84–
19.76)
3.04 (0.90–
10.33)
409, 339
Number of partners of the opposite sex in last
year
0 10.4 (3.8–25.5) 1.00 Ref 0.741 1.00 - 0.687 100, 59
1 14.5 (12.1–
17.4)
1.46 (0.49–4.35) 1.52 (0.43–5.38) 1059, 745
2+ 15.6 (10.2–
23.1)
1.59 (0.49–5.16) 1.28 (0.32–5.06) 215, 115
Total number of lifetime sexual partnersd
1 to 4 5.9 (3.7–9.2) 1.00 Ref <0.001 575, 361
5 to 9 9.9 (6.6–14.4) 1.74 (0.90–3.33) 322, 223
10+ 27.2 (22.1–
33.1)
5.95 (3.41–
10.35)
446, 306
(Continued )
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Table 3. (Continued)
Pgp3 positive Unadjusted OR p Adjusted ORa
(95%CI)
p Denominator (W,
UW)b
% 95% CI OR 95% CI AOR 95% CI
Was a condom used on any occasions in last 4
weeks?
Yes, used on every occasion 10.8 (7.0–16.3) 1.00 Ref 0.046 1.00 - 0.272 285, 181
Yes, used on some occasions 13.0 (7.6–21.2) 1.23 (0.58–2.61) 1.24 (0.54–2.82) 173, 98
No, not used in last 4 weeks 17.6 (14.3–
21.4)
1.76 (1.04–3.00) 1.51 (0.83–2.72) 657, 479
Not had vaginal or anal sex in last 4 weeks 9.7 (5.7–15.8) 0.88 (0.43–1.81) 0.86 (0.39–1.90) 246, 151
Ever been told by a doctor that you have
chlamydia
No 12.8 (10.6–
15.4)
1.00 Ref <0.001 1.00 Ref 0.003 1145, 776
Yes 44.6 (26.9–
63.8)
5.47 (2.47–
12.15)
3.55 (1.53–8.25) 62, 35
Percentage Pgp3 seropositive in men should be interpreted with caution due to the relatively low sensitivity of the assays used to detect a known previous
infection in men (see Methods section).
aAdjusted for lifetime sexual partners only.
bAnalyses were conducted on those with non-missing data on the variable(s) of interest. Denominator totals vary due to item-missingness. W: Weighted;
UW: Unweighted.
cIMD: index of multiple deprivation; LSOA: Lower super output area
dIncludes partners of both the opposite and of the same sex.
doi:10.1371/journal.pone.0152810.t003
Fig 2. Pgp3 seroprevalence by reported numbers of lifetime sexual partners (among 16- to 44-year olds,
HSE2010 & HSE2012).
doi:10.1371/journal.pone.0152810.g002
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Fig 3. Pgp3 seroprevalence by year (16- to 24-year-old women, HSE 1994 to 2012). Solid lines show point estimates; dashed
lines show 95% confidence intervals. Unweighted denominators: 1994–1996, n = 1,555; 2001–2002, n = 1097; 2008–2012, n = 709.
doi:10.1371/journal.pone.0152810.g003
Fig 4. Pgp3 seroprevalence by birth cohort and year of age (16- to 24-year-old women, HSE 1994 to 2012). Unweighted
denominators: High screening exposure (born 1992–1996), n = 185; Partial screening exposure (born 1984–1991), n = 853; Limited
screening exposure (born 1976–1983), n = 1349; Limited screening exposure (born 1966–1975), n = 929. See online appendix (S1
File) for details of denominators by year of age.
doi:10.1371/journal.pone.0152810.g004
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social desirability bias. However, as data were self-reported and as household members could
be present during booklet completion[21], underreporting remains possible[29].
Given the sensitivity of the double-antigen ELISA (82.9% in women; 54.4% in men)[17],
the proportion of the population ever infected with chlamydia would be even higher than we
estimated. Pgp3 antibodies were detected among a small proportion of people who did not
report having ever had sexual intercourse (4.5% of women; 3.5% of men; Fig 2). This may be
due to under-reporting of sexual experience or to false positives that would be expected from
low prevalence populations. None of the sexually-experienced 16- to 17-year-old women were
seropositive for Pgp3. This finding was unanticipated, as we would expect some evidence of
previous infection in this age group. In the third National Survey of Sexual Attitudes and Life-
styles (Natsal-3; a nationally-representative survey of adults living in Britain, conducted in
2010–12), twenty-nine of percent 16- to 24-year-olds reported having first had sex before age
16[30]. Furthermore, chlamydia diagnoses have been reported in national surveillance data
among those aged under 16 years[31]. Although we would, therefore, expect a proportion of
16- to 17- year-old women to have been infected with chlamydia, our analysis was limited by
the sample size available (n = 18); a larger sample size might have detected evidence of previ-
ous infection among the youngest age group. Seroprevalence patterns in men should be
interpreted with caution given the relatively low sensitivity of chlamydia antibody to detect
previous infection in men[16;17]. This lower sensitivity, which has also been noted with other
assays[17], may indicate that men are less likely to mount a persistent antibody response to C.
trachomatis infection.
The percent Pgp3 seropositive among those reporting a previous diagnosis of chlamydia
was lower than the estimated sensitivity of the assays used (e.g. 64.7% (51.9–75.6) in women
versus 82.9% (77.0–88.8) sensitivity of the double-antigen ELISA)[15]. This is similar to find-
ings from the New Zealand Dunedin Multidisciplinary Health and Development Study studied
by Horner et al., where 74.6% (61.6–85.0) of 448 women aged 38 years with previous history of
chlamydia infection had detectable Pgp3 antibody using the double-antigen ELISA [15]. This
may be due to reporting error in chlamydia history as people can forget or misunderstand the
STI they had, or alternatively reflect differences in the age of participants in our study com-
pared with the clinical population used for assay validation, thus indicating some waning of
detectable antibodies over time. In their 2013 study, Horner et al demonstrated that Pgp3 sero-
positivity measured using the indirect ELISA alone declines with time since infection, with the
most apparent declines seen in the first six months after diagnosis[20]. However, Horner
et al’s more recent study of female participants in a cohort study in New Zealand, which used
the double-antigen ELISA, found that over 95% of women who were seropositive at age 26
were still seropositive at age 38, suggesting persistence up to at least 12 years following infec-
tion[17]. This suggests our study, which incorporated the double-antigen assay into the detec-
tion strategy, will be less subject to declines in detectable antibodies over time than if the
indirect ELISA alone had been used. Nevertheless, given the potential impact of assay sensitiv-
ity on interpreting trends in seroprevalence, the duration of antibody response needs further
clarification. Work is therefore ongoing to better characterise Pgp3 antibody response using
the two Pgp3 ELISAs used in relation to time since infection and number of previous infec-
tions[32].
Pgp3 seroprevalence plateaued in women from around the age of 30. This may reflect a
reduction in acquisition of infection in older women, which would be consistent with the prev-
alence of current chlamydia infection peaking in those under-25 [33]. This may also reflect dif-
ferences in cumulative exposure to chlamydia infection by birth cohort, given the decline in
STI rates observed in the mid-1980s to the mid-1990s and the subsequent rise[34]. A previous
population-based study in the Netherlands using the Medac CT IgG ELISA found a less
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marked relationship with age than was seen in our study, as well as a lower overall seropreva-
lence (9.8% in women; 5.7% in men aged 15 to 39[35]). These differences may be due to the
difference in assay sensitivity to detect a previous known infection (Medac: 46.2% versus dou-
ble-antigen ELISA: 82.9%)[17].
We found no significant change in age-specific Pgp3 seroprevalence between 2008 and
2012 and no difference in seroprevalence between birth cohorts exposed to different levels of
opportunistic chlamydia screening. This is perhaps surprising given the increase in chlamydia
control efforts over the last decade. There are a number of possible explanations for this lack of
a decline. First, high levels of chlamydia screening may not have been in place long enough to
effect a change in age-specific cumulative incidence, given that the NCSP was only nationally-
implemented in 2008. Secondly, our analysis of trends over time was limited by the number of
samples available; a larger sample might have had power to detect a change. However it should
be noted that the observed (non-significant) decrease in seroprevalence between 2008 and
2012 was especially influenced by seroprevalence in 2012 among 20- to 24-year-olds (S2 Fig).
In contrast to our study, Horner et al found a significant decline in Pgp3 seroprevalence from
2007 to 2010 among 17- to 24-year-old women[36]. The difference in findings may be due to
sources of sera (Horner et al used residual sera submitted to laboratories for routine investiga-
tions rather than a probability sample) or the different time-periods investigated. However an
alternative explanation is also suggested by our analysis. We found that at least a third of
women will be infected with chlamydia at some point over their lifetime and that the majority
of seropositive individuals in HSE2010/2012 had never been diagnosed. We propose that this
combination of high lifetime cumulative incidence and large undiagnosed fraction offers a
partial explanation for the absence of a decline in seroprevalence among 16- to 24-year-old
women up to 2012.
Our findings suggest that screening activity up to 2010/2012 was leaving the majority of
infections in under-25 year-olds undiagnosed. Nevertheless, 64% of Pgp3 seropositive 16- to
24-year olds had been tested for chlamydia at some time before the interview even if they had
never been diagnosed. This suggests that the timing and frequency of testing in relation to
infection warrants attention. Current guidance recommends chlamydia testing on change of
sexual partner[8], but the extent to which this is done in practice is unclear. We also found
that Pgp3 seropositivity was higher among women who reported younger age at first sex
and seroprevalence increased sharply from age 16 to 25. Consistent with previous studies
[17;36;37], this emphasises the importance of adolescence and young adulthood as periods
when chlamydia prevention and screening activities are needed to prevent development of
adverse consequences.
Our findings can also be used to inform future research in the field of chlamydia epidemiol-
ogy and control. First, our estimates of age-specific cumulative incidence and proportion of
infections diagnosed should be considered as potential data sources to parameterise and vali-
date mathematical models of chlamydia screening and better understand C. trachomatis infec-
tion transmission dynamics. Secondly, our population-based estimates of Pgp3 seroprevalence
by age and numbers of sexual partners provide important information for designing, imple-
menting and evaluating future chlamydia vaccination programmes. Although not yet available,
there have been several advancements towards a chlamydia vaccine in recent years[38;39]. In
the event of a safe and efficacious vaccine becoming available, having an understanding of
exposure to chlamydia in the general population and a means of measuring burden of chla-
mydia infection will be essential. Our study provides information to inform the development
of such programmes and demonstrates the utility of antibody seroprevalence as a biological
outcome measure for evaluating chlamydia control and prevention efforts, including future
vaccination programmes.
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In conclusion, we have demonstrated a novel method of assessing population levels of prior
chlamydia infection using a sensitive and specific testing strategy. A significant decrease in the
proportion of the population aged 16 to 24 ever infected with chlamydia following the national
implementation of opportunistic chlamydia screening has not yet been demonstrated. This
may be due to insufficient time since implementation of widespread screening, limited statisti-
cal power, or to the extent of infection within the general population and the high proportion
of infections that, up to 2012, appeared to have gone undiagnosed. We propose that use of the
Pgp3 indirect and double-antigen ELISAs in representative population samples of women pro-
vides a valid and generalisable approach to evaluating the impact of public health interventions
to control chlamydia transmission.
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